Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance. We've worked with Public Health England (PHE) to bring together our information on managing ...

A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving ...

The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...

This means mothers whose babies need antibiotics could leave hospital sooner and complete treatment at home with full clinical support, potentially reducing their hospital stay by up to 2.7 days. All ...

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...

There are commercial access agreements for encorafenib and binimetinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for vorasidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults. This guidance updates and replaces NICE ...